Skip to main content

Velocity Clinical Research acquires Meridian Clinical Research creating largest global research sites business

Dr. Paul Evans, Chief Executive and President of Velocity

Dr. Paul Evans, Chief Executive and President of Velocity
Dr. Paul Evans, Chief Executive and President of Velocity

DURHAM, N.C., Dec. 15, 2022 (GLOBE NEWSWIRE) — Velocity Clinical Research (“Velocity”), the leading integrated research site organization, today announces its acquisition of Meridian Clinical Research for an undisclosed amount. The deal makes Velocity the largest dedicated research site organization in the world with approximately 80 sites in the U.S. and Europe, including a tech hub in Hyderabad, India.

Meridian is a multi-specialty site organization for Phase I-IV clinical trials. As a result of this acquisition, Velocity will have sites in 25 U.S. states, employing over 1500 clinical research professionals.

Dr. Paul Evans, President and Chief Executive of Velocity said, “Having admired Nicole Osborn and the Meridian team’s approach to clinical research for some time now, I am particularly pleased to welcome them to Velocity. The combination of two of the best businesses in this sector moves the needle for clients, changing the relationship from transactional to strategic.

A multi-site business of our size means biopharma and Clinical Research Organizations can circumvent the individual site-selection process, dramatically reducing the time needed to activate sites and recruit patients, which speeds up drug development.”

Velocity’s integrated model reduces the site selection process by 6-8 months. Consequently, Sponsors and Clinical Research Organizations (CRO) have additional foresight and planning time to resource, activate, recruit and deliver clinical trials. Post acquisition, the company will have in excess of one million patients in its database to tap for future studies and provide data to better inform protocol design.

Velocity will continue to make significant investment into technology, driving superior site performance in terms of patient recruitment and engagement, and create tools needed for decentralized trials, which is growing in importance.

Nicole Osborn, who founded Meridian in 1999 will stay with the company to ensure a smooth integration before stepping back from day-to-day management, said, “I am very proud of the company my team and I have built. Meridian has played a major role in drug development that communities across the globe rely upon today, including as a premier site network in the development of COVID-19 vaccines. I’d like to pay tribute to the entire Meridian workforce who have helped to make us the outstanding organization that Velocity is acquiring today.”

Velocity’s sites are fully integrated via a centralized infrastructure and common technology backbone, allowing for superior patient enrollment and consistent, high-quality data delivery. As a result, CROs and biopharma companies can benefit from simplified access to international clinical research.

Since GHO’s investment in 2021, when Velocity had 14 sites, the clinical trials space has seen a number of entrants ranging from small individual funds to large global firms.

Evans added, “We expect to see further merger and acquisition activity in the sites industry next year and beyond. The consolidation of consolidators signals a maturing market and Velocity is leading the charge. This acquisition establishes a major player in the clinical research arena and we intend to use this as a platform to build the next stage of our evolution.”

Meridian Clinical Research was advised by Edgemont Partners investment banking firm, with Ice Miller LLP providing legal advice. For Velocity Clinical Research Ropes & Gray LLP provided legal advice while Alvarez and Marsal provided financial advice.

Notes to Editors

A full list of Velocity’s locations can be found on its website.

About Velocity Clinical Research

Velocity Clinical Research, headquartered in Durham, N.C., is the leading integrated site organization for clinical trials, offering dedicated site capabilities to help biopharmaceutical and contract research organization customers find the right patients for their studies. Velocity supports global drug development in primarily conducting phase II and phase III clinical trials. The company has nearly 80 locations globally, including a technology hub in Hyderabad, India.

We place the care of the patient at the heart of everything we do. With over 35 years of experience running sites and nearly 8,000 studies completed, Velocity has refined its patient recruitment strategies while maintaining a focus on delivering timely and reliable data quality. https://velocityclinical.com.

About Meridian Clinical Research

Meridian Clinical Research was founded by Nicole Osborn in 1999 in Omaha, NE. More than 20 years later, Meridian has grown from a single dedicated research center to a network of more than 35 clinical research sites and 90 principal investigators across North America. Meridian’s principal investigators are deeply engaged in clinical research, and every research site is staffed by highly trained research personnel.

Meridian partners with pharmaceutical and biotechnology companies to conduct clinical trials for everything from flu vaccines and acne, to chronic conditions like multiple sclerosis and Alzheimer’s disease, and has enrolled more than 80,000 participants across more than 3,400 research studies to date. https://www.mcrmed.com/.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/eb28e27e-5a24-4fb5-ac5d-c2a4c2c614e5

CONTACT: Media contact

Katie Evans
kevans@velocityclinical.com
+447903073570

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.